Loading...
Loading...
NTLA| Name | Value |
|---|---|
| Revenues | 12.0M |
| Cost of Revenue | 2.3M |
| Gross Profit | 9.7M |
| Operating Expense | 143.1M |
| Operating I/L | -131.1M |
| Other Income/Expense | 8.9M |
| Interest Income | 12.7M |
| Pretax | -122.2M |
| Income Tax Expense | -15.0M |
| Net Income/Loss | -122.2M |
Intellia Therapeutics, Inc. is a genome editing company specializing in the development of in vivo and ex vivo therapeutics. Its in vivo programs, including NTLA-2001 and NTLA-2002, focus on treating transthyretin amyloidosis and hereditary angioedema, as well as liver-focused programs for various genetic disorders. The company's ex vivo pipeline features NTLA-5001 for acute myeloid leukemia and engineered cell therapies for oncological and autoimmune disorders. Intellia also offers CRISPR/Cas9 system tools. The company generates revenue through license and collaboration agreements with pharmaceutical companies for the development of potential products for the treatment of genetic diseases.
